

## Radioligand therapy: multidisciplinary collaboration for health system readiness

Radioligand Therapy Meeting

Thursday 25  
November  
16:30 - 18:00

### Location

Nikos Skalkotas Hall

16:30 - 16:35

### Welcome and introduction

H. Van Poppel, Leuven (BE)

[Learning objectives of this presentation](#)

Why is a multidisciplinary approach to prostate cancer care important? How radioligand therapy lends itself to this approach?

16:35 - 16:45

### Radioligand therapy: what is radioligand therapy and how it could be used in prostate cancer?

J. Buscombe, Cambridge (GB)

[Learning objectives of this presentation](#)

What is radioligand therapy? How it could be used in prostate cancer and what is the potential for the future?

16:45 - 16:55

### What could radioligand therapy mean for patients?

E. Briers, Hasselt (BE)

[Learning objectives of this presentation](#)

The patient perspective: reflections upon the potential impact of radioligand therapy on people with prostate cancer.

16:55 - 17:10

### The readiness assessment framework for radioligand therapy

C. Merkel

[Learning objectives of this presentation](#)

Presentation of the readiness framework incorporating:

- Importance of readiness for prostate cancer treatment.
- Why we need a systems approach to planning.
- Key findings/policy priorities as they relate to prostate cancer (UK and US pilots)

17:10 - 17:50

### Discussion: how can the clinical community create a ready system for radioligand therapy?

[Learning objectives of this presentation](#)

A multidisciplinary moderated panel discussion on the unique challenges of integrating radioligand therapy into cancer care.

Q and A from the audience.

#### *Discussants*

A. Charalambous, Limassol (CY)

J. Kunikowska, Warszawa (PL)

B.A. Hadaschik, Essen (DE)

S. Gillessen Sommer, Bellinzona (CH)

G. De Meerleer, Leuven (BE)

17:50 - 18:00

### Conclusions

H. Van Poppel, Leuven (BE)

